口服或阴道米索前列醇用于引产与剖宫产风险
本单中心回顾性队列研究比较口服与阴道米索前列醇引产结局,口服组剖宫产率32% vs 阴道组21%(P=.04),校正后aOR 2.01(95%CI 1.07-3.76),口服组阴道分娩时间更长(41 vs 31小时,P=.01),结论认为口服米索前列醇可能与剖宫产风险增加及阴道分娩时间延长相关。
要点
- 口服米索前列醇组剖宫产率32%,高于阴道组的21%(P=.04)。
- 校正混杂因素后,口服米索前列醇的剖宫产校正比值比为aOR 2.01(95%CI 1.07-3.76)。
- 初产妇中口服组剖宫产率41% vs 阴道组28%(aOR 2.79;95%CI 1.26-6.19)。
核心结论
- 与阴道米索前列醇相比,口服米索前列醇可能与剖宫产风险增加及阴道分娩时间延长相关。
研究设计与样本
- 本研究为单中心回顾性队列研究,在三级学术医疗中心开展,比较2013-2014年使用25微克阴道米索前列醇与2014-2015年使用50微克口服米索前列醇的引产结局。
- 口服米索前列醇组138例,阴道米索前列醇组138例;主要结局为剖宫产。
主要发现
- 口服米索前列醇组剖宫产率32%,阴道米索前列醇组21%(P=.04)。
- 校正后口服米索前列醇的剖宫产aOR 2.01(95%CI 1.07-3.76)。
- 初产妇中口服米索前列醇组剖宫产率41%,阴道米索前列醇组28%(aOR 2.79;95%CI 1.26-6.19)。
- 口服米索前列醇组阴道分娩时间41小时,阴道米索前列醇组31小时(P=.01)。
- 子宫过度收缩在阴道米索前列醇组更常见(20% vs 11%;P=.04)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether cervical ripening with oral misoprostol increases cesarean delivery risk and prolongs time to vaginal delivery compared with vaginal misoprostol in a predominantly overweight population. METHODS: This single center, retrospective cohort study was performed at a tertiary care academic medical center and compared labor induction outcomes with vaginal misoprostol to outcomes with oral misoprostol after a complete institutional shift to oral misoprostol. Labor induction using 25 micrograms vaginal misoprostol in 2013-2014 was compared with 50 micrograms oral misoprostol in 2014-2015. The primary outcome was cesarean delivery. Secondary outcomes included time to vaginal delivery, uterine tachysystole, maternal hemorrhage, and composite adverse neonatal outcomes. Demographics and outcomes were analyzed using standard statistical tests. Multivariable regression models accounting for potential confounders were created for the primary and secondary outcomes with adjusted odds ratios (aOR) as the measures of effect. RESULTS: There were 138 women in the oral and 138 women in the vaginal misoprostol groups. In the overall cohort, the median (interquartile range) body mass index was 31.7 (28.2-36.8) and most women (72%) were of either black or Hispanic race or ethnicity. The frequency of cesarean delivery was higher in the oral than the vaginal misoprostol group (32% vs 21%; P=.04). The adjusted odds of cesarean was higher with oral misoprostol (aOR 2.01; 95% CI 1.07-3.76). Among nulliparous women, the frequency of cesarean delivery was 41% in the oral and 28% in the vaginal misoprostol groups (aOR 2.79; 95% CI 1.26-6.19). Women had a longer time to vaginal delivery in the oral compared with vaginal misoprostol group (41 vs 31 hours respectively, P=.01). Tachysystole occurred more frequently with vaginal misoprostol (20% vs 11%; P=.04). CONCLUSION: Compared with vaginal misoprostol, oral misoprostol may be associated with increased risk of cesarean delivery and longer time to vaginal delivery.
引用
- Handal-Orefice RC, Friedman AM, Chouinard SM, et al. Oral or Vaginal Misoprostol for Labor Induction and Cesarean Delivery Risk. Obstet Gynecol. 2019. PMID: 31188317. doi:10.1097/AOG.0000000000003274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。